See Letter page e39.

Commentary: Rethinking surgical protocols in the COVID-19 era

Daniel T. Engelman, MD,^{a,b} and
Rakesh C. Arora, MD, PhD^{c,d}

In the current era of the severe acute respiratory syndrome coronavirus 2 (ie, coronavirus disease 2019 [COVID-19]) pandemic, the Centers for Disease Control and Prevention recently published recommendations for the care of our patients. There were additional modifications provided by the American College of Surgeons particularly pertinent to surgical patients and personnel.¹ Both organizations have recommended stopping elective cases and to implement logical, tiered general precautions, but there has been less granular guidance addressing specific aspects of perioperative care and management. Although by and large the surgical community has complied with this request, the infectious risk of COVID-19 and its life-threatening complications remains a reality for those patients requiring urgent/emergency surgery and for the surgeons and health care professionals who perform these operations.

In this issue of the *Journal*, Mayeur and colleagues² suggest that the routine practice of nasal screening for *Staphylococcus aureus* before surgery may compromise health care professional safety during the swabbing and testing process. Routine universal decontamination using intranasal povidone–iodine has been shown to decrease the surgical-site infection rate by more than 50% among patients undergoing elective orthopedic surgery,³ and as such under normal circumstances, this would seem a prudent approach in cardiac surgical patients.⁴

With inadvertent transmission of COVID-19 as a possible consideration, it is imperative to reduce potential risk of

Daniel T. Engelman, MD, and Rakesh C. Arora, MD, PhD

CENTRAL MESSAGE

In the current era of the SARS-CoV-2 (ie, COVID-19) pandemic, routine preoperative nasal swabbing for identification of Staph carriers in our patient population should be reconsidered.

infection to our health care workers, perhaps our most precious resource in our anti-COVID-19 armamentarium. Logic dictates that until a more critical assessment is made of the risk posed by this practice, routine preoperative nasal swabbing for the identification of Staph carriers in our patient population should be reconsidered. The risk of bacterial resistance with routine, rather than selective, nasal decontamination is far outweighed by the advantage of avoiding any additional COVID-19 infection risk in our health care workers. Thus, we suggest the routine decontamination of all patients needing urgent/emergent procedures, without preoperative testing to determine colonization.

References

1. Interim Guidance for Healthcare Facilities: Preparing for Community Transmission of COVID-19 in the United States. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/healthcare-facilities/guidance-hcf.html>. Accessed March 15, 2020.
2. Mayeur N, Berthoumieu P, Charbonneau H. Does nasal screening for *Staphylococcus aureus* before surgery compromise healthcare professional safety in the COVID-19 era? *J Thorac Cardiovasc Surg*. 2020;160:e39.
3. Bebko SP, Green DM, Awad SS. Effect of a preoperative decontamination protocol on surgical site infections in patients undergoing elective orthopedic surgery with hardware implantation. *JAMA Surg*. 2015;150:390-5.
4. Hong JC, Saraswat MK, Ellison TA, Magruder JT, Crawford T, Gardner JM, et al. *Staphylococcus aureus* prevention strategies in cardiac surgery: a cost-effectiveness analysis. *Ann Thorac Surg*. 2018;105:47-53.

From the ^aHeart and Vascular Program, Baystate Health and ^bUniversity of Massachusetts Medical School–Baystate, Springfield, Mass; and ^cDepartment of Surgery, Section of Cardiac Surgery, Max Rady College of Medicine, University of Manitoba and ^dCardiac Sciences Program, St. Boniface Hospital, Winnipeg, Manitoba, Canada.

Disclosures: Dr Arora has received an unrestricted educational grant from Pfizer Canada, Inc, and honoraria from Mallinckrodt Pharmaceuticals, Abbott Nutrition, and Edwards Lifesciences for work unrelated to this work. Dr Engelman consults for Edwards Lifesciences.

Received for publication April 7, 2020; revisions received April 7, 2020; accepted for publication April 8, 2020; available ahead of print April 13, 2020.

Address for reprints: Rakesh C. Arora, MD, PhD, St. Boniface Hospital Winnipeg, CR3012 – 369 Tache Ave, Winnipeg, Manitoba, R2H 2A6, Canada (E-mail: rakeshcarora@gmail.com).

J Thorac Cardiovasc Surg 2020;160:e41

0022-5223/\$36.00

Copyright © 2020 by The American Association for Thoracic Surgery

<https://doi.org/10.1016/j.jtcvs.2020.04.015>